Dr. Reddy's Laboratories Ltd., of Hyderabad, India, said it filed three 505(b)(2) new drug applications to the FDA, seeking approval of DFD-01, a corticosteroid delivered in a non-irritating spray platform, intended for the treatment of patients suffering from psoriasis; DFD-09, a modified-release oral tetracycline intended for the treatment of rosacea; and DFN-11, a drug-device combination product intended to treat acute migraine.